Related Experiment Video
Updated: Mar 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use
Sebastiano Buti1, Melissa Bersanelli
1Oncology Unit, University Hospital of Parma. sebabuti@libero.it.
Abstract:
After the publication of the results of CHAARTED trial, we discuss an issue of clinical interest about toxicity of this treatment and its prophylactic management. The low rates of neutropenia reported in CHAARTED trial population, compared to those of similar previous studies, need further clarifications about the use of G-CSF, not described by the authors, in order to reproduce this hematological tolerability also in everyday clinical practice. We highlighted the importance of toxicity management and prevention in order to better apply the results of this promising trial in real life patient care.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Differentiation of Common Myeloid Progenitor Cells
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Treatment Resistent Cancers

